SBIR-STTR Award

Quantitative Biomimetic MRI Breast Tissue and Tumor Phantom: Toward a Comprehensive PHA
Award last edited on: 8/2/21

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$399,778
Award Phase
1
Solicitation Topic Code
401
Principal Investigator
Todor Karaulanov

Company Information

CaliberMRI Inc (AKA: CMRI~QalibreMD Inc~Qalibre MD Inc~QMD)

4909 Nautilus Court North Suite 121
Boulder, CO 80301
   (720) 828-7674
   info@qmri.com
   www.qmri.com
Location: Single
Congr. District: 02
County: Boulder

Phase I

Contract Number: 75N91020C00056
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2020
Phase I Amount
$399,778
Research statistics have confirmed that breast cancer early detection saves lives. It is important that the patient is staged properly with the lowest possible side effects (morbidity). The best personalized treatment with almost immediate feedback on efficacy is critical to addressing the spread of breast cancer in a timely manner. Creation of a biomimetic quantitative MRI platform to guide the optimization of MRI scanners will enable and improve early breast cancer detection by providing a basis for quantitative assessment of tumor progression during treatment, and providing a means for cancer staging based on qMRI biomimics of primary tumor and lymph nodes. It is believed that this will drive research on using MRI to assess lymph nodal status and ultimately avoid many of the currently required lymph node biopsies and lymph node removal.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----